Schizophrenia, Paranoid: Clinical Trials

3 trials for Schizophrenia, Paranoid, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3

Follow Schizophrenia, Paranoid: new trials by email Literature Review of Schizophrenia, Paranoid trials Research Report on Schizophrenia, Paranoid

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Transcutaneous Non-invasive Vagus Nerve Stimulation (t-VNS) in the Treatment of Schizophrenia
t-VNS verum, t-VNS placebo - Schizophrenia
Phase 2Completedcerbomed GmbH202010-03-012012-09-12
MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016)
MK0249, Comparator: Placebo (unspecified) - Paranoid Schizophrenia
Phase 2CompletedMerck Sharp & Dohme LLC552007-12-012015-08-03
MK0557 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0557-027)
MK0557, Comparator: Placebo (unspecified) - Paranoid Schizophrenia, Schizophrenia
Phase 2CompletedMerck Sharp & Dohme LLC502007-09-012015-08-21

Narrower conditions

Schizophrenia (2)  ·  Delusions (1)  ·  Dementia (1)  ·  Hallucinations (1)  ·  Illusions (1)  ·  Mental Disorders (1)  ·  Neuroleptic Malignant Syndrome (1)  ·  Psychotic Disorders (1)  ·  Schizophrenia, Catatonic (1)  ·  Schizophrenia, Disorganized (1)  ·  Tardive Dyskinesia (1)

Broader conditions

Schizophrenia Spectrum and Other Psychotic Disorders (3)  ·  Mental Disorders (2)  ·  Basal Ganglia Diseases (1)  ·  Behavior (1)  ·  Behavioral Symptoms (1)  ·  Brain Diseases (1)  ·  Central Nervous System Diseases (1)  ·  Chemically-Induced Disorders (1)  ·  Dyskinesia, Drug-Induced (1)  ·  Dyskinesias (1)  ·  Movement Disorders (1)  ·  Nervous System Diseases (1)  ·  Neurobehavioral Manifestations (1)  ·  Neurocognitive Disorders (1)  ·  Neurologic Manifestations (1)

Interventions

MK-0249 (1)  ·  spiro(cyclohexane-1,3'(1'H)-furo(3,4-C)pyridine)-4-carboxamide, N-(1-(2-fluorophenyl)-1h-pyrazol-3-yl)-1'-oxo-, trans- (1)

Sponsors

Merck Sharp & Dohme LLC (2)  ·  cerbomed GmbH (1)

Countries

Germany (1)

Results publications

PMID 23523692